NewGenIvf Group Limited Class A Ordinary Shares (NIVF) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
NewGenIvf Group Limited Class A Ordinary Shares stock (NIVF) is currently trading at $2.01. NewGenIvf Group Limited Class A Ordinary Shares PS ratio (Price-to-Sales) is 0.21. Analyst consensus price target for NIVF is $900.00. WallStSmart rates NIVF as Underperform.
- NIVF PE ratio analysis and historical PE chart
- NIVF PS ratio (Price-to-Sales) history and trend
- NIVF intrinsic value — DCF, Graham Number, EPV models
- NIVF stock price prediction 2025 2026 2027 2028 2029 2030
- NIVF fair value vs current price
- NIVF insider transactions and insider buying
- Is NIVF undervalued or overvalued?
- NewGenIvf Group Limited Class A Ordinary Shares financial analysis — revenue, earnings, cash flow
- NIVF Piotroski F-Score and Altman Z-Score
- NIVF analyst price target and Smart Rating
NewGenIvf Group Limited Class A
📊 No data available
Try selecting a different time range
NIVF Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · NewGenIvf Group Limited Class A Ordinary Shares (NIVF)
NIVF trades at a significant discount to its Graham intrinsic value of $3305.41, offering a 100% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
NewGenIvf Group Limited Class A Ordinary Shares (NIVF) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, price/sales, price/book. Concerns around market cap and operating margin. Mixed signals suggest waiting for clearer direction before acting.
NewGenIvf Group Limited Class A Ordinary Shares (NIVF) Key Strengths (4)
Every $100 of shareholder equity generates $161 in profit
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Keeps $381 of every $100 in revenue as net profit
Supporting Valuation Data
NewGenIvf Group Limited Class A Ordinary Shares (NIVF) Areas to Watch (4)
Losing money on operations
Revenue declining -12.90%, a shrinking business
Very low institutional interest at 0.47%
Micro-cap company with very limited liquidity and high volatility
NewGenIvf Group Limited Class A Ordinary Shares (NIVF) Detailed Analysis Report
Overall Assessment
This company scores 49/100 in our Smart Analysis, earning a D+ grade. Out of 8 metrics analyzed, 4 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.21), Price/Book (0.03) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 160.50%, Profit Margin at 381.20%.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Institutional Own.. Growth concerns include Revenue Growth at -12.90%, which may limit upside. Profitability pressure is visible in Operating Margin at -195.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 160.50% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -12.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NIVF Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NIVF's Price-to-Sales ratio of 0.21x trades at a 19% premium to its historical average of 0.18x (73th percentile). The current valuation is 42% below its historical high of 0.37x set in Feb 2025, and 617% above its historical low of 0.03x in Jan 2025. Over the past 12 months, the PS ratio has expanded from ~0.2x, reflecting growing market expectations outpacing revenue growth.
Compare NIVF with Competitors
Top MEDICAL CARE FACILITIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for NewGenIvf Group Limited Class A Ordinary Shares (NIVF) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
NewGenIvf Group Limited Class A Ordinary Shares faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 5M with 13% decline year-over-year. Profit margins are strong at 381.2%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 160.5% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Revenue contracted 13% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact NewGenIvf Group Limited Class A Ordinary Shares.
Bottom Line
NewGenIvf Group Limited Class A Ordinary Shares faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About NewGenIvf Group Limited Class A Ordinary Shares(NIVF)
NASDAQ
HEALTHCARE
MEDICAL CARE FACILITIES
USA
NewGenIvf Group Limited (NIVF) is a prominent provider in the reproductive health sector, specializing in advanced fertility solutions and innovative in vitro fertilization (IVF) services. The company is dedicated to enhancing success rates in assisted reproductive techniques and addresses the growing global demand for fertility treatments through a well-established network of clinics and strategic partnerships. Positioned for growth within a rapidly expanding market, NIVF is well-equipped to capitalize on emerging opportunities, reinforcing its commitment to helping individuals and couples realize their dreams of parenthood.